title: [Aflibercept in clinical practice].
abstract: In this article we have tried to evaluate first clinical experience with the effectiveness and safety of aflibercept in the treatment of the wet form of age related macular degeneration in all types of subretinal neovascular membranes for the period of the first 10 months of treatment in our clinic.
authors.forename: J
authors.initials: J
authors.lastname: Bajaček
authors.forename: A
authors.initials: A
authors.lastname: Bieliková
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D041623:Tomography, Optical Coherence; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor